Answers are grounded in this paper and cite their sources.
Osteoarthritis is a progressive degenerative joint disease characterized by high disability rates and an increasing global prevalence. Current treatment methods primarily provide symptomatic relief but cannot prevent or reverse disease progression, highlighting the urgent need for effective early interventions. Exosomes, as small extracellular vesicles secreted by most cell types, carry a wide range of bioactive molecules, including proteins, lipids, and nucleic acids (mRNAs, microRNAs, and lncRNAs). These molecular cargos play a crucial role in intercellular communication, immune modulation, and tissue homeostasis. Increasing evidence indicates the therapeutic potential of exosomes in the management of osteoarthritis. This review summarizes recent advances in the understanding of exosomes derived from diverse cell sources—such as mesenchymal stem cells, chondrocytes, and synovial cells—and discusses their mechanisms in modulating osteoarthritis pathology. Additionally, we also discuss the promise of exosomes as next-generation drug delivery systems, emphasizing targeted modification strategies ( e.g. , genetic engineering and surface chemistry) and advanced delivery technologies ( e.g. , hydrogel composites and 3D printing platforms). Finally, we also summarized the clinical trials of exosome-based therapy for osteoarthritis and the main obstacles and challenges it faces. By integrating mechanistic insights with translational innovations, this review underscores both the unique advantages and current challenges of exosome-based treatment and delivery in osteoarthritis. Finally, we propose a forward-looking perspective to guide the design of precise and efficient exosome-based interventions aimed at improving clinical outcomes in osteoarthritis.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: